Literature DB >> 27531699

Genomic complexity of multiple myeloma and its clinical implications.

Salomon Manier1,2, Karma Z Salem1,2, Jihye Park1,2, Dan A Landau3,4, Gad Getz2,5, Irene M Ghobrial1,2.   

Abstract

Multiple myeloma (MM) is a genetically complex disease that evolves from pre-malignant stages, such as monoclonal gammaopathy of undetermined significance and smouldering multiple myeloma, and progresses to symptomatic MM; this continuum provides a unique framework to study the sequential genomic evolution of MM. In the past 5 years, results from large-scale whole-exome sequencing studies have provided new insights into the clonal heterogeneity and evolution of the disease. Moreover, the recurrent co-occurrence of genomic events helps to dissect the genomic complexity underlying tumour progression. According to the primary genetic events involved in tumorigenesis, MM tumours are hierarchically subdivided into hyperdiploid and non-hyperdiploid subtypes; subsequently, secondary genetic events lead to tumour progression. In this Review, we describe the 'driver' gene alterations involved in the development and progression of MM, with a focus on the sequential acquisition of the main genomic aberrations. We also provide valuable insight into the clonal heterogeneity and clonal evolution of the disease, as well as into the therapeutic implications of a comprehensive understanding of the genomic complexity of MM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27531699     DOI: 10.1038/nrclinonc.2016.122

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  129 in total

1.  A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

Authors:  Wee Joo Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; Peter Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2005-05-26       Impact factor: 22.113

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Authors:  Omar Abdel-Wahab; Virginia M Klimek; Alisa A Gaskell; Agnes Viale; Donavan Cheng; Eunhee Kim; Raajit Rampal; Mark Bluth; James J Harding; Margaret K Callahan; Taha Merghoub; Michael F Berger; David B Solit; Neal Rosen; Ross L Levine; Paul B Chapman
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

4.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

5.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Authors:  Jonathan J Keats; Tony Reiman; Christopher A Maxwell; Brian J Taylor; Loree M Larratt; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

Review 6.  Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.

Authors:  David González; Mirjam van der Burg; Ramón García-Sanz; James A Fenton; Anton W Langerak; Marcos González; Jacques J M van Dongen; Jesus F San Miguel; Gareth J Morgan
Journal:  Blood       Date:  2007-07-18       Impact factor: 22.113

7.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities.

Authors:  G Tricot; B Barlogie; S Jagannath; D Bracy; S Mattox; D H Vesole; S Naucke; J R Sawyer
Journal:  Blood       Date:  1995-12-01       Impact factor: 22.113

8.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Authors:  Brian A Walker; Christopher P Wardell; Alex Murison; Eileen M Boyle; Dil B Begum; Nasrin M Dahir; Paula Z Proszek; Lorenzo Melchor; Charlotte Pawlyn; Martin F Kaiser; David C Johnson; Ya-Wei Qiang; John R Jones; David A Cairns; Walter M Gregory; Roger G Owen; Gordon Cook; Mark T Drayson; Graham H Jackson; Faith E Davies; Gareth J Morgan
Journal:  Nat Commun       Date:  2015-04-23       Impact factor: 14.919

9.  Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.

Authors:  Daniel Chubb; Niels Weinhold; Peter Broderick; Bowang Chen; David C Johnson; Asta Försti; Jayaram Vijayakrishnan; Gabriele Migliorini; Sara E Dobbins; Amy Holroyd; Dirk Hose; Brian A Walker; Faith E Davies; Walter A Gregory; Graham H Jackson; Julie A Irving; Guy Pratt; Chris Fegan; James Al Fenton; Kai Neben; Per Hoffmann; Markus M Nöthen; Thomas W Mühleisen; Lewin Eisele; Fiona M Ross; Christian Straka; Hermann Einsele; Christian Langer; Elisabeth Dörner; James M Allan; Anna Jauch; Gareth J Morgan; Kari Hemminki; Richard S Houlston; Hartmut Goldschmidt
Journal:  Nat Genet       Date:  2013-08-18       Impact factor: 38.330

10.  Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Authors:  P Leif Bergsagel; W Michael Kuehl; Maurizio Affer; Marta Chesi; Wei-Dong G Chen; Jonathan J Keats; Yulia N Demchenko; Anna V Roschke; Scott Van Wier; Rafael Fonseca
Journal:  Leukemia       Date:  2014-02-12       Impact factor: 11.528

View more
  156 in total

1.  Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14).

Authors:  Alice Cleynen; Mehmet Samur; Aurore Perrot; Laure Buisson; Sabrina Maheo; Mariateresa Fulciniti; Michel Attal; Nikhil Munshi; Hervé Avet-Loiseau; Jill Corre
Journal:  Blood       Date:  2018-11-14       Impact factor: 22.113

2.  18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System.

Authors:  Sung-Hoon Jung; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Seo-Yeon Ahn; Seung-Yeon Jung; Seung-Shin Lee; Moo-Rim Park; Deok-Hwan Yang; Jae-Sook Ahn; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-05       Impact factor: 9.236

Review 3.  Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.

Authors:  Daphné Dupéré-Richer; Jonathan D Licht
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

Review 4.  Reconstructing the evolutionary history of multiple myeloma.

Authors:  Francesco Maura; Even H Rustad; Eileen M Boyle; Gareth J Morgan
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

5.  C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma.

Authors:  Sai-Qun Luo; De-Hui Xiong; Jiang Li; Guangdi Li; Yali Wang; Jia-Ming Zhang; Xiu-Fen Bu; Wei-Xin Hu; Jingping Hu
Journal:  Oncogene       Date:  2020-02-27       Impact factor: 9.867

6.  Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Authors:  N Bolli; G Biancon; M Moarii; S Gimondi; Y Li; C de Philippis; F Maura; V Sathiaseelan; Y-T Tai; L Mudie; S O'Meara; K Raine; J W Teague; A P Butler; C Carniti; M Gerstung; T Bagratuni; E Kastritis; M Dimopoulos; P Corradini; K Anderson; P Moreau; S Minvielle; P J Campbell; E Papaemmanuil; H Avet-Loiseau; N C Munshi
Journal:  Leukemia       Date:  2017-12-06       Impact factor: 11.528

7.  Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Authors:  Pankaj Yadav; Maximilian Merz; Elias K Mai; Asta Försti; Anna Jauch; Hartmut Goldschmidt; Kari Hemminki
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

8.  Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.

Authors:  Smith Giri; Scott F Huntington; Rong Wang; Amer M Zeidan; Nikolai Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff; Natalia Neparidze
Journal:  Blood Adv       Date:  2020-05-26

9.  Multiplex Immunofluorescence of Bone Marrow Core Biopsies: Visualizing the Bone Marrow Immune Contexture.

Authors:  Denise K Walters; Diane F Jelinek
Journal:  J Histochem Cytochem       Date:  2019-12-19       Impact factor: 2.479

Review 10.  MicroRNA Transfer Between Bone Marrow Adipose and Multiple Myeloma Cells.

Authors:  Luna Soley; Carolyne Falank; Michaela R Reagan
Journal:  Curr Osteoporos Rep       Date:  2017-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.